Assembly Biosciences

78 articles with Assembly Biosciences

• Assembly Biosciences to Wind-Down Microbiome ProgramCompany will prioritize resources to focus on advancement of novel HBV therapeutic portfolio

  12/8/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV), today announced that it will wind-down its microbiome program, enabling the company to prioritize resources and focus on the advancement of its pipeline of novel core inhibitors for chronic HBV.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Dec 04, 2020

  12/4/2020

  Assembly Biosciences, Inc. announced grants of stock options to three new employees to purchase an aggregate of 14,520 shares of the Company’s common stock with an exercise price of $5.66 per share, the closing price of Assembly Bio’s common stock on December 1, 2020.

• Assembly Biosciences Appoints Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

  11/17/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Nicole S. White, PhD, as Senior Vice President of Pharmaceutical Development and Manufacturing

• Assembly Biosciences and Door Pharmaceuticals Sign Collaboration and Option Agreement to Develop a Novel Class of HBV Core Protein Modulators

  11/16/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Door Pharmaceuticals, LLC today announced that the companies have signed an exclusive, two-year collaboration and option agreement focused on the development of a novel class of hepatitis B virus (HBV) core protein modulators. Door Pharmaceuticals’ innovative discovery platform targets functions of core protein distinct from viral assembly and that have the potential to interfere with v

• Assembly Biosciences Presents Data from HBV Core Inhibitor Programs in Poster Sessions at the 2020 AASLD The Liver Meeting Digital Experience™

  11/13/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that data from its HBV core inhibitor programs and related research will be highlighted during four poster sessions – including two late-breakers – at the 2020 American Association for the Study of Liver Diseases (AASLD

• Assembly Biosciences Reports Grant Under Nasdaq Listing Rule 5635(c)(4)

  11/6/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced a grant of stock options to a new employee to purchase 6,520 shares of the Company’s common stock with an exercise price of $14.75 per share, the closing price of Assembly’s common stock on November 2, 2020. The stock optio

• 

  Assembly Biosciences Falls Short with Hepatitis B Drug in Phase 2 Study

  11/6/2020

  Assembly Biosciences, Inc. provided an update on Nov. 5 of its ongoing Phase 2 extension study, Study 211, examining vebicorvir (VBR, or ABI-H0731) in patients with hepatitis B virus infection.

• Assembly Biosciences Reports Third Quarter 2020 Financial Results and Business Update

  11/5/2020

  Assembly Biosciences, Inc., a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus and diseases associated with the microbiome, reported financial results and a business update for the third quarter ended September 30, 2020.

• Assembly Biosciences Provides Update on the Ongoing Phase 2 Extension Study of Vebicorvir in Patients with Chronic Hepatitis B Virus Infection

  11/5/2020

  HBV field’sfirstcore inhibitor combination study to assess off-treatmentresponse has not achieved a meaningful rate ofsustained virologic response

• Multiple Abstracts Highlighting Assembly Biosciences’ Hepatitis B Core Inhibitor Development Programs Accepted for Presentation at the 2020 AASLD The Liver Meeting Digital Experience™

  11/2/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced that data from its HBV core inhibitor research and development programs as well as a collaborative translational study using Assembly Bio’s sensitive HBV nucleic acid assays are featured in four abstracts accepted for presentation during The Liver Meeting Digital Experience™ (TLMdX)

• 

  BioSpace Movers & Shakers, Oct. 23

  10/23/2020

  Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.

• Assembly Biosciences Appoints Gina Consylman to Board of Directors

  10/20/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced the appointment of Gina Consylman to its board of directors

• 

  BioSpace Movers & Shakers, Oct. 16

  10/16/2020

  Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.

• Assembly Biosciences CEO Dr. John McHutchison Named Recipient of the Prestigious Advance 2020 Global Impact AwardDr. McHutchison Recognized for Critical Achievements in Developing Curative Treatments for Chronic Hepatitis

  10/15/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, today announced that John McHutchison AO, MD – the company’s CEO and president– was named the recipient of the Advance 2020 Global Impact award. The Advance awards recognize the work of remarkable global Australians making an extraordinary

• Assembly Biosciences Announces October Conference Participation

  10/5/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB), a clinical-stage biotechnology company developing innovative therapeutics targeting hepatitis B virus (HBV) and diseases associated with the microbiome, announced participation in two upcoming conferences focused on HBV. ICE-HBV Serum Biomarkers Virtual Workshop 2020 Panel: What are the virological and immunological gaps that need to be addressed? What biomarkers are most needed to

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Oct 02, 2020

  10/2/2020

  Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 31,520 shares of the Company’s common stock with an exercise price of $17.29 per share, the closing price of Assembly’s common stock on October 1, 2020.

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Sep 04, 2020

  9/4/2020

  Assembly Biosciences, Inc. announced grants of stock options to five new employees to purchase an aggregate of 86,000 shares of the Company’s common stock with an exercise price of $20.14 per share, the closing price of Assembly’s common stock on September 1, 2020.

• Clinical Data from Assembly Biosciences’ HBV Core Inhibitors Presented at The Digital International Liver CongressTM EASL 2020

  8/28/2020

  Assembly Biosciences, Inc. announced that clinical data for its lead HBV core inhibitor vebicorvir, its second-generation core inhibitor ABI-H2158, as well as its highly sensitive HBV assays were highlighted during The Digital International Liver Congress™, the Annual Meeting of the European Association for the Study of the Liver.

• Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection

  8/27/2020

  Assembly Biosciences, Inc. (Nasdaq: ASMB) and Arbutus Biopharma Corporation (Nasdaq: ABUS), today announced that the companies have entered into a clinical collaboration agreement to evaluate Assembly’s lead hepatitis B virus (HBV) core inhibitor candidate ABI-H0731 in combination with Arbutus’ proprietary GalNAc delivered RNAi therapeutic AB-729 and standard-of-care nucleos(t)ide reverse transcriptase inhibitor

• Assembly Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Aug 07, 2020

  8/7/2020

  Assembly Biosciences, Inc. announced grants of stock options to two new employees to purchase an aggregate of 13,000 shares of the Company’s common stock with an exercise price of $23.08 per share, the closing price of Assembly’s common stock on August 3, 2020.